Food and Drug Administration commentary on methodological issues in negative symptom trials.
US Food and Drug Administration, Division of Psychiatry Products, Silver Spring, MD, USA. Thomas.Laughren@fda.hhs.gov
Thomas
T
Laughren
Robert
R
Levin
D000342:Affective Symptoms / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D003299:Cooperative Behavior; D003625:Data Collection / Q000379:methods; D004345:Drug Industry; D004359:Drug Therapy, Combination; D004493:Education; D006801:Humans; D033183:Interdisciplinary Communication; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011594:Psychometrics; D015203:Reproducibility of Results; D012107:Research Design; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014481:United States; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents
Schizophr Bull. 2005 Jan;31(1):5-19
15888422
Schizophr Bull. 2006 Apr;32(2):220-2
16079389
Schizophr Bull. 2006 Apr;32(2):250-8
16221995